Bayer completes acquisition Teva Pharmaceutical

Bayer completes acquisition of Teva Pharmaceutical

10:00 AM, 4th January 2013
Bayer completes acquisition of Teva Pharmaceutical
Dr Joerg Reinhardt, Chief Executive Officer, Bayer HealthCare.

LEVERKUSEN, GERMANY: Bayer HealthCare has received the necessary regulatory approval from the Federal Trade Commission to complete the acquisition of the US -based animal health business of Teva Pharmaceutical Industries Ltd. As announced in September 2012, Bayer will pay up to $145 million which includes an upfront payment of $60 million plus a total of $85 million in milestone payments, which are linked to the successful and timely achievement of manufacturing and sales targets. The transaction includes a manufacturing site in St Joseph, Missouri and around 300 employees.

The new portfolio will include a strong anti-infectives franchise and will enable Bayer to be present in all major therapeutic areas. The companion animal products features a full line of dermatology products sold under the DVM Pharmaceutical brand, including such products as Malaseb, HyLyt, Relief and others. Further companion animal products include a broad line of nutraceuticals encompassing joint and gastro-intestinal products including the Synovi brands. Food animal products acquired from Teva include a wide range of anti-infectives in addition to parasiticides, anti-inflammatory brands and reproductive hormones.

“This acquisition fits nicely with our strategic goals. It allows us to strengthen and broaden our range of animal care solutions in the US market,” said Dr Joerg Reinhardt, Chief Executive Officer, Bayer HealthCare.

© WOC News 



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Recycling symbols on plastics

The number inside the triangle which is embossed on the bottom of plastic containers identifies the type of plastic from which the container is made. ...

Read more
Unilever to phase out microplastics by 2015

LONDON, UK: Unilever, the maker of Vaseline, Axe deodorants and Dove soaps, among other cosmetic and hygiene products, will phase out the use of micro ...

Read more
BP starts production at Skarv field in Norway

LONDON, UK: BP and partners announced the successful start of production from the Skarv field in the Norwegian Sea, one of a series of new major ups ...

Read more
Fluor’s Glenn Gilkey named Chairman of CII for 2013

IRVING, US: Glenn Gilkey, Senior Vice President, Human Resources and Administration, Fluor Corporation, was recently chosen by the Construction Indust ...

Read more
Eurotecnica bags Melamine plant contract in China

XINJIANG, CHINA: Eurotecnica has been awarded a contract for 80,000 tonne per year single train High Pressure Melamine plant to be implemented in Chin ...

Read more
BASF to increase global capacity for 1,6-hexanediol

LUDWIGSHAFEN, GERMANY: BASF will increase its annual global capacity for manufacturing the chemical intermediate 1,6-hexanediol (HDO) by more than 20 ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X